Volume 28, Number 12—December 2022
CME ACTIVITY - Synopsis
Clinical and Epidemiologic Characteristics and Therapeutic Management of Patients with Vibrio Infections, Bay of Biscay, France, 2001–2019
Table 3
Characteristic |
No sepsis, n = 42 |
Septic shock, n = 13 |
p value | ||||
---|---|---|---|---|---|---|---|
No. | % (95% CI) | No. | % (95% CI) | ||||
Patient sex | |||||||
M | 35 | 83 (72–95) | 10 | 77 (54–100) | 0.685 | ||
F |
7 |
17 (5–28) |
3 |
23 (0.2–46) |
|||
Underlying conditions | |||||||
Heart failure | 18 | 43 (28–58) | 6 | 46 (19–73) | Referent | ||
Neoplasia | 6 | 14 (4–25) | 4 | 31 (6–56) | 0.223 | ||
Diabetes | 7 | 17 (5–28) | 1 | 8 (0–22) | 0.664 | ||
Kidney failure | 5 | 12 (2–22) | 2 | 15 (0–35) | 0.664 | ||
Immune disease | 5 | 12 (2–22) | 2 | 15 (0–35) | 0.664 | ||
Hemopathy | 3 | 7 (0–15) | 2 | 15 (0–35) | 0.582 | ||
Liver disease | 2 | 5 (0–11) | 3 | 23 (0–46) | 0.318 | ||
Alcohol use disorder | 3 | 7 (0–15) | 4 | 31 (6–56) | 0.102 | ||
Preexisting wound | 6 | 14 (4–25) | 0 | 0 (0–0) | 0.317 | ||
Digestive surgery |
4 |
10 (1–18) |
2 |
15 (0–35) |
0.618 |
||
Species | |||||||
V. alginolyticus | 10 | 24 (11–37) | 4 | 31 (6–56) | |||
V. parahaemolyticus | 14 | 33 (19–48) | 5 | 38 (12–65) | |||
V. cholerae non-O1/O139 | 8 | 19 (7–31) | 2 | 15 (0–35) | |||
V. vulnificus | 6 | 14 (4–25) | 1 | 8 (0–22) | |||
Other Vibrio species |
4 |
10 (1–18) |
1 |
8 (0–22) |
|||
Outcome | |||||||
Recovered | 40 | 95 (89–100) | 7 | 54 (27–81) | 0.001 | ||
Died |
2 | 5 (0–11) | 6 | 46 (19–73) |
*Median patient age (+SD) was 60 (+21.4) for no sepsis and 61 (+15.3) for septic shock.
1Current affiliation: Centre Hospitalier Troyes, Troyes, France.
2Current affiliation: Centre Hospitalier d’Auxerre, Auxerre, France.
Page created: November 21, 2022
Page updated: November 21, 2022
Page reviewed: November 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.